Role of Wnts in prostate cancer bone metastases

Journal of Cellular Biochemistry

Volumn 97, Issue 4, 2006, Pages 661-672

  Hall, Christopher L ^a   Kang, Sona ^a   MacDougald, Ormond A ^a   Keller, Evan T ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CCGCB   (United States)

Author keywords

Bone; DKK; Metastasis; Osteoblast; Prostate cancer; Wnt

Indexed keywords

CYSTEINE; ENDOTHELIN 1; GLYCOPROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN; VASCULOTROPIN; WNT PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE MASS; BONE METASTASIS; BONE REMODELING; CELL PROLIFERATION; EMBRYO DEVELOPMENT; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOSCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH;

ADULT; BONE NEOPLASMS; CARCINOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MODELS, BIOLOGICAL; OSTEOGENESIS; OSTEOLYSIS; OSTEOSCLEROSIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; WNT PROTEINS;

ANIMALIA;

EID: 33645006198     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20735     Document Type: Article

References (92)

1. Abrams H, Spiro R, Goldstein N. 1950. Metastases in carcinoma. Cancer 3:74-85.
2. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F. 2003. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18:960-974.
3. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. 2001. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nature Cell Biology 3:683-686.
4. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA. 2005. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 102:3324-3329.
5. Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS. 2004. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 18:1222-1237.
6. Boland GM, Perkins G, Hall DJ, Tuan RS. 2004. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93:1210-1230.
7. Boyce BF, Yoneda T, Guise TA, 1999. Factors regulating the growth of metastatic cancer in bone. [Review] [125 refs]. Endocr Relat Cancer 6:333-347.
8. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521.
9. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. 1999. beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 155:1033-1038.
10. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. 2000. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Human Pathology 31:578-583.
11. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, Kitajewski J, Wang CY. 2001. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 152:87-96.
12. Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA. 2003. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 278:45969-45977.
13. Chirgwin JM, Mohammad KS, Guise TA. 2004. Tumorbone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 4:308-318.
14. Church VL, Francis-West P. 2002. Wnt signalling during limb development. [Review] [119 refs]. Int J Dev Biol 46:927-936.
15. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. 2003. Zoledronic Acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9:295-306.
16. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM. 1999. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18:2883-2891.
17. Cronauer MV, Schulz WA, Ackermann R, Burchardt M. 2005. Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol 26:1033-1040.
18. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET. 2004. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 64:994-999.
19. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. 2005. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65:8274-8285.
20. Day TF, Guo X, Garrett-Beal L, Yang Y. 2005. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8:739-750.
21. De Boer J, Siddappa R, Gaspar C, van Apeldoorn A, Fodde R, van Blitterswijk C. 2004. Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells. Bone 34:818-826.
22. Derfoul A, Carlberg AL, Tuan RS, Hall DJ. 2004. Differential regulation of osteogenic marker gene expression by Wnt-3a in embryonic mesenchymal multipotential progenitor cells. Differentiation 72:209-223.
23. Farr GH 3rd, Ferkey DM, Yost C, Pierce SB, Weaver C, Kimelman D. 2000. Interaction among GSK-3, GBP, axin, and APC in Xenopus axis specification. J Cell Biol 148:691-702.
24. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. 2003. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9:2587-2597.
25. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2005. Canonical WNT signaling promotes osteogenesis by directly stimulating RUNX2 gene expression. J Biol Chem 280(39):33132-33140.
26. Giles RH, van Es JH, Clevers H. 2003. Caught up in a Wnt storm: Wnt signaling in cancer. [Review] [353 refs]. Biochimica et Biophysica Acta 1653:1-24.
27. Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G. 2005. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764.
28. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523.
29. Grotewold L, Ruther U. 2002. The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J 21:966-975.
30. Guise TA. 2000. Molecular mechanisms of osteolytic bone metastases. Cancer 88:2892-2898.
31. Hall CL, Tsan R, Mugnai G, Mazar A, Radinsky R, Pettaway CA. 2004. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). Prostate 59:167-176.
32. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. 2005. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65:7554-7560.
33. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kanzler KW. 1998. Identification of c-MYC as a target of the APC pathway, [comment]. Science 281:1509-1512.
34. Hecht A, Vleminckx K, Stemmler MP, van Roy F, Kemler R. 2000. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. E1MBO J 19:1839-1850.
35. Herynk MH, Tsan R, Radinsky R, Gallick GE. 2003. Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis 20:291-300.
36. Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C. 2005. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8:727-738.
37. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO. 2005. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 280:21162-21168.
38. Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F. 2005. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132:49-60.
39. Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL. 1994. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 54:2615-2621.
40. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML. 1995. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147:386-396.
41. Hwang SG, Ryu JH, Kim IC, Jho EH, Jung HC, Kim K, Kim SJ, Chtin JS. 2004. Wnt-7a causes loss of differentiated phenotype and inhibits apoptosis of articular chondrocytes via different mechanisms. J Biol Chem 279:26597-26604.
42. Jackson A, Vayssiere B, Garcia T, Newell W, Baron R, Roman-Roman S, Rawadi G. 2005. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 36:585-598.
43. Jeon MJ, Kim JA, Kwon SH, Kim SW, Park KS, Park SW, Kim SY, Shin CS. 2003. Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem 278:23270-23277.
44. Jiang W, Hiscox S, Matsumoto K, Nakamura T. 1999. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. [Review] [376 refs]. Crit Rev Oncol Hematol 29:209-248.
45. Johnson ML. 2004. The high bone mass family-The role of Wnt/Lrp5 signaling in the regulation of bone mass. J Musculoskelet Neuronal Interact 4:135-138.
46. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA 2nd, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L. 2002. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303-314.
47. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS. 2001. Prostate carcinoma skeletal metastases: Cross talk between tumor and bone. Cancer Metastasis Rev 20:333-349.
48. Kennell JA, MacDougald OA. 2005. Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms. J Biol Chem 280:24004-24010.
49. Kikuchi A. 2000. Regulation of beta-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 268:243-248.
50. Koeneman KS, Yeung F, Chung LW. 1999. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. [Review] [153 refs]. Prostate 39:246-261.
51. 2+ pathway: A new vertebrate Wnt signaling pathway takes shape. [Review] [27 refs]. Trends Genet 16:279-283.
52. Kuhnert F, Davis CR, Wang HT, Chu P, Lee M, Yuan J, Nusse R, Kuo CJ. 2004. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci USA 101:266-271.
53. Lejeune S, Huguet EL, Hamby A, Poulsom R, Harris AL. 1995. Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res 1:215-222.
54. Levy L, Neuveut C, Renard CA, Chameau P, Branchereau S, Gauthier F, Van Nhieu JT, Cherqui D, Petit-Bertron AF, Mathieu D, Buendia MA. 2002. Transcriptional activation of interleukin-8 by beta-catenin-Tcf4. J Biol Chem 277:42386-42393.
55. Li J, Mizukami Y, Zhang X, Jo WS, Chung DC. 2005a. Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology 128:1907-1918.
56. Li X, Liu P, Liu W, Maye P, Zhang J, Zhang Y, Hurley M, Guo C, Boskey A, Sun L, Harris SE, Rowe DW, Ke HZ, Wu D. 2005b. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 37:945-952.
57. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET. 2001. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47:212-221.
58. Little RD, Carulli JP, DelMastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML. 2002. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19.
59. Logan CY, Nusse R. 2004. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781-810.
60. Logothetis CJ, Lin SH. 2005. Osteoblasts in prostate cancer metastasis to bone. [Review] [83 refs]. Nat Rev Cancer 5:21-28.
61. Longo KA, Kenneil JA, Ochocinska MJ, Ross SE, Wright WS, MacDougald OA. 2002. Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J Biol Chem 277:38239-38244.
62. Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C. 2001. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. [see comment]. Nature 411:321-325.
63. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A, Niehrs C. 2002. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417:664-667.
64. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, Wang X, Zarnegar R, Michalopoulos GK. 2002. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 62:2064-2071.
65. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. 2001. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432-4436.
66. Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, Chen L, Tsukui T, Gomer L, Dorward DW, Glinka A, Grinberg A, Huang SP, Niehrs C, Belmonte JC, Westphal H. 2001. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Developmental Cell 1:423-434.
67. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. 2002. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 277:17933-17943.
68. Muller T, Bain G, Wang X, Papkoff J. 2002. Regulation of epithelial cell migration and tumor formation by beta-catenin signaling. Exp Cell Res 280:119-133.
69. Mundy GR. 1997. Mechanisms of bone metastasis. Cancer 80:1546-1556.
70. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA. 2003. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169:1143-1149.
71. Nuttall ME, Gimble JM. 2004. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 4:290-294.
72. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. 2000. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407:535-538.
73. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW. 1995. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154:293-298.
74. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. 2003. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18:1842-1853.
75. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. 2003. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423:409-414.
76. Roodman GD. 2004. Mechanisms of bone metastasis.[see comment]. [Review] [86 refs]. N Engl J Med 350:1655-1664.
77. Rubin J, Chung LW, Fan X, Zhu L, Murphy TC, Nanes MS, Rosen CJ. 2004. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis. Prostate 58:41-49.
78. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK. 2005. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146:1727-1736.
79. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben Ze'ev A. 1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:5522-5527.
80. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr. 2003. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.[see comment]. N Engl J Med 349:2483-2494.
81. Van De Wetering M, Cavallo R, Dooijes D, van Beest M, van Es J, Loureiro J, Ypma A, Hursh D, Jones T, Bejsovec A, Peifer M, Mortin M, Clevers H. 1997. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88:789-799.
82. van der Horst G, van der Werf SM, Farih-Sips H, van Bezooijen RL, Lowik CW, Karperien M. 2005. Down-regulation of Wnt Signaling by Increased Expression of Dickkopf-1 and -2 is a Prerequisite for Late-Stage Osteoblast Differentiation of KS483 Cells. J Bone Miner Res 20:1867-1877.
83. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W. 2003. Six novel missense mutations in the LDL receptor-related protein 5. LRP5 gene in different conditions with an increased bone density. Am J Hum Genet 72:763-771.
84. Veeman MT, Axelrod JD, Moon RT. 2003. A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. [Review] [94 refs]. Dev Cell 5:367-377.
85. Westendorf JJ, Kahler RA, Schrpeder TM. 2004. Wnt signaling in osteoblasts and bone diseases. Gene 341:19-39,
86. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. 1999. Expression of CD44 in Ape and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154:515-523.
87. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR 3rd, Nusse R. 2003. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423:448-452.
88. Yanagawa S, van Leeuwen F, Wodarz A, Klingensmith J, Nusse R. 1995. The dishevelled protein is modified by wingless signaling in Drosophila. Genes Dev 9:1087-1097.
89. Yang Y. 2003. Wnts and wing: Wnt signaling in vertebrate limb development and musculoskeletal morphogenesis. [Review] [139 refs]. Birth Defects Res C Embryo Today 69(4):305-317.
90. Zechner D, Fujita Y, Hulsken J, Muller T, Walther I, Taketo MM, Crenshaw EB 3rd, Birchmeier W, Birchmeier C. 2003. beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev Biol 258:406-418.
91. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. 2001. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235-1244.
92. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. 2003. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 63:7883-7890.